...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Reproduction, Contraception, Obstetrics and Gynecology >Ferricarboxy maltose to treat iron deficiency anemia in pregnancy: is it a feasible option?
【24h】

Ferricarboxy maltose to treat iron deficiency anemia in pregnancy: is it a feasible option?

机译：亚铁羧基麦芽糖治疗妊娠期缺铁性贫血：是否可行？

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Iron deficiency is a common cause of anaemia in pregnancy which influences the health of mother and developing fetus. Intravenous (IV) iron preparations are considered, when oral iron therapy is ineffective or intolerant. Ferric carboxymaltose is an IV preparation that can be given with ease of administration and better tolerated. The aim of this study was to assess the efficacy and safety of IV ferric carboxymaltose in pregnant mother with all grades of anemia in the second and third trimester. Methods: This is a prospective observational study where 44 pregnant women with iron deficiency anemia [IDA] received ferric carboxymaltose up to 15mg/kg in second and third trimester. The parameters that were taken into account, to assess the effectiveness of the treatment was repeat haemoglobin [Hb] measurements and the subjective sense of wellbeing in the patient. The safety of the drug was analysed by continuous fetal heart rate [FHR] monitoring during the infusion and observation of any adverse reactions. Results: Ferric carboxymaltose intravenous infusion significantly increased Hb levels above baseline values in all women. The Increase in Hb levels were observed at 3- and 6-weeks post infusion therapy. FHR monitoring did not show any drug related unfavourable effect on the fetus. Of the 44 women interviewed, 33 (75%) women reported sense of well-being, 7 (15.9%) women could not feel any difference after the infusion and 4 (9.1%) patients could not comment. No serious adverse effects were noticed but minor side effects occurred in 3 (6.8%) patients. Conclusions: This prospective study showed safety and efficacy of ferric carboxymaltose in pregnancy with IDA which is consistent with available observational data.
机译：背景：铁缺乏症是妊娠贫血的常见原因，会影响母亲和胎儿的健康。当口服铁疗法无效或不耐受时，可以考虑静脉（IV）铁制剂。羧基麦芽糖铁是一种静脉注射制剂，可以轻松给药并具有更好的耐受性。这项研究的目的是评估在妊娠中期和晚期所有级别的贫血中，IV型羧甲基麦芽糖对孕妇的疗效和安全性。方法：这是一项前瞻性观察性研究，其中44名患有缺铁性贫血[IDA]的孕妇在妊娠中期和晚期接受了最高15mg / kg的羧化麦芽糖铁。为评估治疗效果而考虑的参数是重复进行的血红蛋白[Hb]测量和患者的主观幸福感。通过在输注期间连续进行胎儿心率[FHR]监测并观察任何不良反应来分析药物的安全性。结果：所有妇女静脉内注射羧甲基麦芽糖铁均使血红蛋白水平明显高于基线值。输注治疗后3周和6周观察到Hb水平升高。 FHR监测未显示对胎儿的任何药物相关不利影响。在接受采访的44位女性中，有33位（75％）女性报告了幸福感，有7位（15.9％）女性在输注后感觉没有任何差异，有4位（9.1％）患者没有发表评论。未观察到严重的不良反应，但3例（6.8％）患者发生了轻微的副作用。结论：这项前瞻性研究显示了IDA妊娠中羧化麦芽糖铁的安全性和有效性，与现有的观察数据一致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号